Harmony Plus Holding

Harmony Plus Holding is a cross-border biopharmaceutical holding and investment firm based in Silicon Valley and Hong Kong. The company is primarily recognized for its 2013 strategic joint venture with Aerami Therapeutics (formerly Dance Biopharm) to commercialize the inhaled insulin candidate Dance 501 in China and other Pacific Rim markets. Harmony Plus Holding leverages its extensive network of financial institutions and regulatory consultants to bridge Western medical innovation with the Asia-Pacific healthcare sector. Beyond its holding activities, the firm operates as a venture capital entity with a focus on healthcare, technology, and education. It provides critical support to its partners for navigating complex regulatory pathways and scaling operations in international markets. The company remains a key facilitator for Western biotech firms seeking access to the Chinese pharmaceutical landscape.